2022
Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial
Hricik D, Armstrong B, Alhamad T, Brennan D, Bromberg J, Bunnapradist S, Chandran S, Fairchild R, Foley D, Formica R, Gibson I, Kesler K, Kim SJ, Mannon R, Menon M, Newell K, Nickerson P, Odim J, Poggio E, Sung R, Shapiro R, Tinckam K, Vincenti F, Heeger P. Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial. Journal Of The American Society Of Nephrology 2022, 34: 145-159. PMID: 36195441, PMCID: PMC10101585, DOI: 10.1681/asn.2022040454.Peer-Reviewed Original ResearchConceptsBiopsy-proven acute rejectionBK virus infectionIntravenous infliximabPrimary end pointTransplant recipientsKidney transplantVirus infectionDe novo donor-specific antibodiesDeceased donor kidney transplant recipientsRabbit anti-thymocyte globulin (rATG) inductionAnti-thymocyte globulin inductionCLINICAL TRIAL REGISTRY NAMEDonor kidney transplant recipientsNovo donor-specific antibodiesEnd pointPhase 2 clinical trialIFX induction therapyTRIAL REGISTRY NAMEDelayed graft functionDonor-specific antibodiesKidney transplant recipientsDeceased donor kidneysTNF-α productionPrimary transplant recipientsAcute rejection
2017
Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival
Yacoub R, Nadkarni GN, Cravedi P, He JC, Delaney VB, Kent R, Chauhan KN, Coca SG, Florman SS, Heeger PS, Murphy B, Menon MC. Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival. Kidney International 2017, 93: 482-490. PMID: 28965746, DOI: 10.1016/j.kint.2017.07.016.Peer-Reviewed Original ResearchMeSH KeywordsDelayed Graft FunctionGraft RejectionGraft SurvivalHistocompatibilityHistocompatibility TestingHLA AntigensHumansKidney TransplantationPredictive Value of TestsProtective FactorsRegistriesRetrospective StudiesRisk FactorsTime FactorsTissue and Organ ProcurementTreatment OutcomeUnited StatesConceptsDelayed graft functionGraft survivalHLA matchingGraft functionDeceased donor kidney transplant patientsDeceased donor kidney transplant recipientsOne-year acute rejection ratesDeath-censored graft survivalOne-year acute rejectionOPTN/UNOS registryDonor kidney transplant recipientsAcute rejection ratesKidney transplant patientsKidney transplant recipientsOrgan Sharing databaseKidney transplant survivalDegree of HLAStrong independent predictorUNOS registryAcute rejectionGraft outcomeTransplant recipientsTransplant patientsHLA matchIndependent predictors